IPO – Talk Bio

LB Pharmaceuticals Files for $228M IPO to Fund Phase III Schizophrenia Drug

1 day ago talkbio0Tagged Alzheimer 's psychosis, amisulpride, Clinical Nurse Specialists, Depression, Bipolar, IPO, LB-102, Nasdaq, Phase 3 Clinical Trials, Pounds, Schizophrenia, United States Food and Drug Administration

LB Pharmaceuticals; IPO; Phase III trial; schizophrenia; LB-102; biotech; CNS therapeutics; bipolar depression; Alzheimer’s psychosis; amisulpride; FDA; Nasdaq

CNS Pharmaceuticals Pursues Public Offering to Fund Phase 2 GBM Trial After Cost Cuts

2 weeks ago talkbio0Tagged cash position, Clinical Nurse Specialists, Funding, Glioblastoma, IPO, layoffs, multiforme, public entity

CNS Pharmaceuticals; biotech; layoffs; IPO; public offering; phase 2 trial; glioblastoma multiforme; funding; cash position

Odyssey Therapeutics Abandons IPO Plans in Latest Sign of Tough Environment for Biotech Listings

3 months ago talkbio0Tagged Autoimmune, IPO, Market, Odyssey, seconds, turbulence, Withdraw (activity)

Odyssey Therapeutics; IPO; biotech; withdrawal; SEC; market turbulence; autoimmune

Three-Month Drought in U.S. Biotech IPOs: Recent Developments and Context

4 months ago talkbio0Tagged Droughts, IPO, Market, stocks

biotech IPO; biotech market; IPO drought; 2025; biotech fundraising; biotech stocks

Chronic care startup Omada Health files to go public

4 months ago talkbio0Tagged Administration occupational activities, cardiometabolic, Chronic Care Management, Diabetes, digital health, Health, Hinge Health, Hypertensive disease, IPO, musculoskeletal conditions, revenue growth, virtual care

Chronic care management, virtual care, IPO, digital health, diabetes management, cardiometabolic health, hypertension, musculoskeletal conditions, revenue growth, Hinge Health

DualityBio Pursues $200M IPO in Hong Kong Amid Volatile Market Conditions

5 months ago talkbio0Tagged Antibody-Drug, BioNTech, biotech sector, DualityBio, global trade tensions, Hong, Immunostimulating conjugate (antigen), Investments, IPO, Kong, Market, Stock exchange, upheaval

DualityBio, IPO, Hong Kong Stock Exchange, biotech investment, antibody-drug conjugates, BioNTech, market upheaval, global trade tensions, biotech sector growth.

Alcon Secures Control of Aurion Biotech in Strategic Takeover

6 months ago talkbio0Tagged Alcon, AURN001, biotech, Bovichtus, Cell Therapy, CEO, corneal endothelial disease, IPO, stake, Surgical Replantation

Alcon, Aurion Biotech, majority stake, CEO replacement, cell therapy, corneal endothelial disease, AURN001, IPO dispute

Legal Battle Erupts as Deerfield Accuses Alcon of Obstructing Aurion Biotech’s IPO Plans

7 months ago talkbio0Tagged Alcon, biotech, biotech industry, Bovichtus, Chancery, Corporate, court, Deerfield Management, Delaware, governance, IPO, Legal, Public Offering, research, shareholder

Aurion Biotech, Alcon Research, Deerfield Management , Initial Public Offering (IPO), Legal dispute, Biotech industry, Corporate governance, Shareholder rights, Delaware Court of Chancery